FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula Ia, as well as to a pharmaceutical composition for inhibiting mTOR activity and methods of treating diseases or disorders mediated by mTOR.
EFFECT: novel compounds having activity on mTOR, which can be used in the treatment of diseases mediated by said activity, such as cancer or an immune-mediated disease, are obtained.
62 cl, 70 ex, 30 tbl
(Iа)
| Title | Year | Author | Number |
|---|---|---|---|
| C40-, C28- AND C-32-LINKED RAPAMYCIN ANALOGUES AS MTOR INHIBITORS | 2019 |
|
RU2805211C2 |
| DERIVATIVES OF BENZISOXAZOLESULFONAMIDE | 2020 |
|
RU2813356C2 |
| PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS | 2009 |
|
RU2539568C2 |
| COMPOUNDS | 2016 |
|
RU2725616C2 |
| 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 (IKZF2) OF THE IKAROS FAMILY | 2019 |
|
RU2797559C2 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| N1/N2-LACTAM ACETYL-CoA-CARBOXYLASE INHIBITORS | 2011 |
|
RU2540337C2 |
| 1-(4-AMINO-5-BROMO-6-(1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)-1H-PYRAZOL-4-OL AND ITS APPLICATIONS FOR CANCER TREATMENT | 2018 |
|
RU2791531C2 |
| ANTIBODIES TO B7-H3 AND CONJUGATES OF ANTIBODY AND DRUG | 2017 |
|
RU2764651C2 |
| ANTIBODY-STING AGONIST CONJUGATES AND USE THEREOF IN IMMUNOTHERAPY | 2020 |
|
RU2826228C2 |
